EUVIMEDEUVIMED entdecken
BeobachtungsstudieVergleichsstudie

ProGlide‐AngioSeal versus ProGlide‐FemoSeal for vascular access hemostasis posttranscatheter aortic valve implantation

Mohamed Samy iD, Martin Landt, Nader Mankerious iD, Arief Kurniadi, Sultan Alotaibi iD, Ralph Toelg, Mohamed Abdel-Wahab, Holger Nef, Abdelhakim Allali, Gert Richardt, Karim Elbasha iD

Catheterization and Cardiovascular Interventions · 2024

DOI: 10.1002/ccd.31259 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Catheterization and Cardiovascular Interventions, 2024. Verfasst von Mohamed Samy und 10 weiteren Autor:innen. Beteiligte Einrichtung: Cardiology Department, Heart Center Segeberger Kliniken GmbH, Bad Segeberg, Germany. Hauptthemen laut MEDLINE: Hemostatic Techniques, Registries, Vascular Closure Devices, Punctures. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 35 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The hybrid strategy combining plug‐based and suture‐based vascular closure devices (VCD) was introduced as a promising technique for vascular access hemostasis after transcatheter aortic valve implantation (TAVI) with satisfactory outcomes. However, data comparing two plug‐based VCDs each in the combination with a suture‐based VCD, namely ProGlide/AngioSeal (P/AS) with ProGlide/FemoSeal (P/FS) VCDs, is still lacking.

Aims

To compare the 30‐day outcome of the hybrid strategy using P/AS versus P/FS for vascular access site closure after TAVI.

Methods

A retrospective single‐center observational study included 608 patients recruited from a prospective TAVI registry between 2016 and 2022. The composite endpoint was defined as any VCD‐related major vascular complications and/or bleeding more than type 1 according to Valve Academic Research Consortium criteria.

Results

The current study reported a significantly higher rate of composite endpoint in P/AS group, which was driven by a higher rate of major bleeding (5.4% vs. 1.4%, p = 0.036). We also found a higher rate of VCD‐related minor bleeding in P/AS group (16.3% vs. 8.1%, p = 0.013). Successful access site hemostasis was achieved in 71.7% of P/AS group versus 83.1% in P/FS group ( p = 0.006). The presence of anterior wall calcification at the access site was significantly associated with the composite endpoint (adj odds ratio 2.49; 95% confidence interval (1.08–5.75), p = 0.032).

Conclusion

The hybrid strategy for large bore vascular access closure using P/FS showed a potentially better 30‐day outcomes compared with P/AS. The presence of anterior calcification at the access site carries a significant risk of VCD‐related complications.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hemostatic TechniquesRegistriesVascular Closure DevicesPuncturesTranscatheter Aortic Valve ReplacementCatheterization, PeripheralHumansMaleFemaleRetrospective StudiesTreatment OutcomeAgedAged, 80 and overTime FactorsRisk FactorsAortic ValveSuture TechniquesFemoral ArteryHemorrhageAortic Valve Stenosis

Stichwörter der Autor:innen

TAVIfemoral access sitevascular access closure device

Autor:innen und Institutionen

  • Cardiology Department, Heart Center Segeberger Kliniken GmbH, Bad Segeberg, Germany.
  • Cardiology Department, Zagazig University, Sharkia, Egypt.
  • Cardiology Department, Cardiac Centre, King Fahad Armed Forces Hospital, Jeddah, Saudi Arabia.
  • Cardiology Department, Medical Faculty of the Christian-Albrechts-University of Kiel, Kiel, Germany.
  • Cardiology Department, Center for Cardiovascular and Diabetes Medicine, Asklepios Clinic Bad Oldesloe, Bad Oldesloe, Germany.
  • Cardiology Department, Heart Centre Leipzig at the University of Leipzig, Leipzig, Germany.

ORCID-Profile: Mohamed Samy, Nader Mankerious, Sultan Alotaibi, Karim Elbasha

Zitieren

APA

Samy, M., Landt, M., Mankerious, N., Kurniadi, A., Alotaibi, S., Toelg, R., Abdel-Wahab, M., Nef, H., Allali, A., Richardt, G., & Elbasha, K. (2024). ProGlide‐AngioSeal versus ProGlide‐FemoSeal for vascular access hemostasis posttranscatheter aortic valve implantation. Catheterization and Cardiovascular Interventions. https://doi.org/10.1002/ccd.31259

Vancouver

Samy M, Landt M, Mankerious N, Kurniadi A, Alotaibi S, Toelg R, et al. ProGlide‐AngioSeal versus ProGlide‐FemoSeal for vascular access hemostasis posttranscatheter aortic valve implantation. Catheterization and Cardiovascular Interventions. 2024. doi:10.1002/ccd.31259

BibTeX
@article{Samy2024,
  author = {Samy, Mohamed and Landt, Martin and Mankerious, Nader and Kurniadi, Arief and Alotaibi, Sultan and Toelg, Ralph and Abdel-Wahab, Mohamed and Nef, Holger and Allali, Abdelhakim and Richardt, Gert and Elbasha, Karim},
  title = {ProGlide‐AngioSeal versus ProGlide‐FemoSeal for vascular access hemostasis posttranscatheter aortic valve implantation},
  journal = {Catheterization and Cardiovascular Interventions},
  year = {2024},
  doi = {10.1002/ccd.31259}
}
Kostenlos starten →